BONUS CAP-ZERTIFIKAT - ROCHE GS Stock

Certificat

DE000VM4A085

Market Closed - Deutsche Boerse AG 13:40:18 2024-06-20 EDT
311.6 EUR -0.47% Intraday chart for BONUS CAP-ZERTIFIKAT - ROCHE GS
Current month+3.46%
1 month+4.41%
Date Price Change
24-06-20 311.6 -0.47%
24-06-19 313 -0.10%
24-06-18 313.3 +0.94%
24-06-17 310.4 -0.57%
24-06-14 312.2 +0.89%

Delayed Quote Deutsche Boerse AG

Last update June 20, 2024 at 01:40 pm

More quotes

Static data

Product typeCertificats Bonus
Buy / SellCALL
Underlying ROCHE HOLDING AG
IssuerLogo Issuer Vontobel Vontobel
WKN VM4A08
ISINDE000VM4A085
Date issued 2023-10-23
Strike 300 CHF
Maturity 2024-09-20 (92 Days)
Parity 1 : 1
Emission price 294.2
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 313.3
Lowest since issue 283.3
Spread 3.42
Spread %1.09%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
250 CHF
Average target price
278.1 CHF
Spread / Average Target
+11.22%
Consensus